logo

For the Inventor, By the Inventor

Yokohama, Japan

Takashi Shomura

This inventor holds 29 USPTO granted patents, plus 1 CIPO patent, primarily in Antibiotic Development. Top assignee: Meiji Seika Kaisha, Ltd.. Active years: 1976-1993.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takashi Shomura. Retrieved from https://idiyas.com/inventor/takashi-shomura

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29

% Patents Active = 100.0


Average Co-Inventor Count = 6.8

ph-index = 6

Forward Citations = 155(Granted Patents)


Location History:

  • Yokohama, JA (1976 - 1978)
  • Kanagawa, JP (1984 - 1992)
  • Yokohama, JP (1978 - 1993)

Company Filing History:

goldMedal29 out of 382 
 
Meiji Seika Kaisha, Ltd.
 patents

Years Active: 1976-1993

Loading Chart...
Loading Chart...
Areas of Expertise:
Antibiotics
Antiviral Agents
Insecticidal Activity
Duocarmycin
Plasmids
Antitumor
Helminthic Infection
Production Methods
Optical Resolution
Novel Substances
29 patents (USPTO):Explore Patents
1. 5194617 - 2,3-disubstituted-4-hydroxyquinoline derivatives (1993-03-16),
2. 5116815 - PF 1022 substance, method of treating helminthic parasitic infection and (1992-05-26),
3. 5026547 - Compound having insecticidal activity and insecticide composition (1991-06-25),
4. 4994578 - Certain anti-tumor duocarmycin antibiotics from streptomyces (1991-02-19),
5. 4954641 - Novel antitumor antibiotic substance and a method for production thereof (1990-09-04),
6. 4548816 - Antibiotic SF-2288 and its preparation method (1985-10-22),
7. 4536398 - Antiviral agents (1985-08-20),
8. 4460693 - Plasmids derived from Actinomycetes (1984-07-17),
9. 4404218 - Antibiotic SF-2103A substance and process for production thereof (1983-09-13),
10. 4396603 - Novel antibiotic SF-2107 series substance and process for preparing the (1983-08-02),
11. 4376778 - Antibiotic substances and processes for production thereof (1983-03-15),
12. 4316894 - Antibiotic SF-1130-x.sub.3 3 substance and production and use thereof (1982-02-23),
13. 4242327 - Antibiotic SF-2052 substance and production and use thereof (1980-12-30),
14. 4226941 - Process for the optical resolution of (1980-10-07),
15. 4220639 - Antibiotics SF-2050 and SF-2050B substances and production and use (1980-09-02),

Title: Takashi Shomura: Innovator in Pharmaceutical Advancements

Introduction

Takashi Shomura is a prominent inventor based in Yokohama, Japan, known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 29 patents, Shomura's work has been vital in advancing medical treatments and understanding drug interactions.

Latest Patents

Among Shomura's latest innovations are the 2,3-disubstituted-4-hydroxyquinoline derivatives. These compounds represent a general formula designed to exhibit strong antagonistic action on leukotriene D4, potentially benefiting a wide range of therapeutic applications. Additionally, he has developed a novel substance known as PF 1022, which has shown promise in treating helminthic parasitic infections. This substance is produced by cultivating a specific fungal strain capable of generating the compound, highlighting the innovative methods employed in his research.

Career Highlights

Shomura currently works with Meiji Seika Kaisha, Ltd., where he continues to push the boundaries of pharmaceutical science. His commitment to research and development has not only led to patents but has also inspired further innovations within the company.

Collaborations

In his journey as an inventor, Takashi has collaborated with notable colleagues such as Shigeharu Inouye and Taro Niida. These partnerships have enriched his research endeavors, making significant strides in the field of pharmaceutical inventions.

Conclusion

Takashi Shomura's work exemplifies the critical role of innovation in healthcare, particularly through his patent contributions. His dedication to developing effective treatments showcases the necessity of ongoing research and collaboration in addressing medical challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…